Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This case report explores the potential of endoscopic photodynamic therapy (PDT) to downstage locally advanced colon cancer (LACC) and enhance patient quality of life. A young female with obstructive LACC, unresponsive to CapeOX chemotherapy, underwent emergency colostomy followed by dual-route endoscopic PDT. Subsequent neoadjuvant therapy, including TAS-102, targeted agents, and immunotherapy, led to a partial tumor response. This enabled fluorescence-guided radical resection and stoma reversal. The patient achieved favorable postoperative recovery, with symptomatic relief, decreased tumor marker levels, and no evidence of disease (NED). This case demonstrates that endoscopic PDT combined with multimodal systemic therapy can facilitate successful conversion surgery and bowel function restoration in treatment-refractory LACC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pdpdt.2025.104761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perforation that Occurred Right After Sigmoid Colon Cancer Stenting.
Dig Dis Sci
September 2025
Department of Gastrointestinal Surgery, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, No. 63, Xinfeng Road, Meijiang District, Meizhou, 514031, Guangdong, China.
Prostate sparing radical cystectomy and neobladder: institutional long-standing qualified consideration.
J Egypt Natl Canc Inst
September 2025
National Cancer Institute of Cairo University, Giza, Egypt.
Objectives: To balance the extended functional urinary voiding and morbidity outcomes amid Ileal W and Y-shaped contrasted to spherical ileocoecal (IC) orthotopic bladders subsequent prostate-sparing radical cystectomy (PRC) versus standard radical cystoprostatectomy (RC).
Material And Methods: Two hundred eight male bladder cancer patients were grouped into 98 RC followed by 43-W, 31-Y, and 23-IC in comparison to 110 PRC followed by 35-W, 37-Y, and 38-IC. The functional voiding outcomes were determined by detailed patients' interview and urodynamic studies (UDS).
LDH-chitosan bionanocomposites for oncologic applications: A refreshing perspective on the mutual influence through intermolecular forces toward controlled morphology and dispersion.
Int J Biol Macromol
September 2025
Nanotechnology Laboratory, TRANSCEND Research Center, Regional Institute of Oncology, 2-4 General Henri Mathias Berthelot Street, 700483, Iași, Romania; Faculty of Chemistry, Al. I. Cuza University, 11- Carol I Bvd., 700506, Iasi, Romania. Electronic address:
This contribution discusses the design of bionanocomposites based on chitosan and MgAl layered double hydroxides (LDH) for cancer therapy. Compared to other studies, our approach was to pre-adsorb the metal chloride precursors of LDH on chitosan while the solution of metal precursors with and without H provided the acidic environment for polymer dissolution. The structure, morphology and chemical composition of the bionanocomposites were characterized by XRD, FTIR, TG, etc.
View Article and Find Full Text PDFNK cells limit the synergistic anti-tumor effect of PD-1 inhibition and βγ-biased IL-2.
Int J Biol Macromol
September 2025
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China; Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China; Institute of Cell The
Despite its potential as a cancer immunotherapy, wild-type IL-2 is limited by dose-limiting toxicities, including vascular leak syndrome, and its strong activation of regulatory T cells (Tregs), which dampens anti-tumor immunity. These drawbacks are largely driven by IL-2's binding to IL-2Rα, and avoiding this interaction can reduce IL-2-associated toxicities, although it cannot completely eliminate them. To overcome these limitations, βγ-biased IL-2 variants (Non-α-IL-2) have been developed to selectively activate effector T and NK cells.
View Article and Find Full Text PDFSafety of artificial intelligence-assisted optical diagnosis for leaving colorectal polyps in situ during colonoscopy (PRACTICE): a non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
October 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Endoscopy Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Background: Guidelines recommend leaving in situ rectosigmoid polyps diagnosed during colonoscopy that are 5 mm or smaller if the endoscopist optically predicts them to be non-neoplastic. However, no randomised controlled trial has been done to examine the efficacy and safety of this strategy.
Methods: This open-label, multicentre, non-inferiority, randomised controlled trial enrolled adults age 18 years or older undergoing colonoscopy for screening, surveillance, or clinical indications across four Italian centres.